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HRQoL Measure
Baseline
(BL) 1 Mo
p value
(1 Mo
vs BL)
6
Mos
p value
(6 Mos
vs BL)
EQ-5D Summary
Index
0.62 0.72 0.001 0.72 0.001
SF12-PCS† 32.82 39.00 0.001 39.74 0.001
SF12-MCS† 46.18 48.51 0.001 49.98 0.001
EQ-5D: from 0 [death] to 1 [perfect health].
†SF-12: from 0 to 100, with a higher score reflecting a better HRQoL
Conclusions: The ADVANCE study represents the largest, rigorously reported cohort of
HRQoL findings in the TAVI literature. All HRQoL measures significantly improved
compared with baseline at 1 and 6 months. An assessment of HRQoL by patient risk
profile according to EuroSCORE will be presented at the meeting.
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Background: The majority of patients have significant elevations in serum cardiac
biomarkers after transcatheter aortic valve replacement (TAVR) however the prognostic
significance of such elevations is unknown. Our aim was to assess incidence and
prognostic power of biomarker elevations after TAVR.
Methods: Clinical data of patients with aortic stenosis who were subjected to TAVR was
retrospectively analyzed. Myocardial necrosis markers cardiac troponin I (cTnI) and
creatine kinase (CK)-MB] were assessed during hospitalization.
Results: Among 150 TAVR patients, TA patients had significantly higher elevations both
for cTnI (13.814.0 vs. 2.55.8, p 0.001) and CK-MB (28.424.2 vs. 7.48.6, p
0.001) compared with TF patients. Biomarker elevations in TA patients did not have
any predictive power for patient outcome. However, by receiver operator curve analysis,
for TF patients, post-procedural CK-MB (2-fold increase) had high predictive power for
30-day mortality (area under the curve 0.85, p 0.001). Patients with high CK-MB had
higher rates of post-procedural kidney injury (22% vs. 6%, p0.026), in-hospital- (22%
vs. 0%, p 0.001), 30-day- (27% vs. 1.5%, p 0.001), and 1-year mortality (41% vs.
18%, p0.01).
Conclusions: Cardiac biomarker rise post-TAVR is common and more frequent among
TA access patients. A 2-fold increase (7 ng/ml) in CK-MB after TF-TAVR is a
surrogate for poor long-term outcome.
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Background: Transcatheter aortic valve replacement (TAVR) is the first major addition
to the treatment of valvular heart disease in more than a decade, and the number of
patients eligible for valve replacement is likely to increase significantly. As a conse-
quence, little is known about expectations within the cardiology community regarding the
utilization of this new therapy in clinical practice.
Methods: Four days after approval of the first TAVR device in November 2011 by the
U.S. Food and Drug Administration (FDA), we emailed an online questionnaire to 201
cardiologists involved in TAVR research and 461 recent members of the Society of
Cardiac Angiography and Interventions to evaluate anticipated TAVR referral patterns.
Follow-up reminders were sent during the next 4 weeks. Characteristics between
researchers and clinicians were compared using chi-square and t-tests.
Results: Of 205 responses received (31%), the majority of respondents were male (90%),
interventional cardiologists (86%), and working in academic practices (72%). Most
respondents (90%) planned to refer patients for TAVR immediately after the devices are
clinically available, and 70% stated that no more data were needed to confirm TAVR is
safe for clinical use. Although 75% of respondents anticipated referring less than
one-fourth of their patients with severe aortic stenosis for TAVR, 68% believed that
TAVR is equally efficacious as open-heart surgery, and 11% believed that moderate-
surgical risk patients should also be referred for TAVR. When comparing groups of
respondents, those involved in TAVR research studies were more conservative with
regard to anticipated referral patterns, as 81% would refer as soon as TAVR is clinically
available versus 98% of clinical cardiologists (p0.01).
Conclusions: These data provide insight into the expected utilization of TAVR after
FDA approval in November 2011. Despite remarkable enthusiasm and media attention for
TAVR over the past few years, our findings suggest cautious optimism among the U.S.
interventional cardiology community regarding the uptake of this new approach to
managing severe aortic stenosis.
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Background: The SAPIEN 3 transcatheter heart valve (Edwards Lifesciences Inc., USA)
incorporates an enhanced paravalvular sealing system, an active 3-dimensional coaxial
positioning catheter, and is compatible with an ultra-low profile 14 French expandable
sheath.
Methods: As a first-in-human trial the SAPIEN 3 transcatheter heart valve (Edwards
Lifesciences Inc., CA, USA) was implanted in 15 patients with symptomatic severe aortic
stenosis via femoral arterial access with a 14 French expandable sheath. Patients
underwent transthoracic echocardiography and multidetector computed tomography both
before and after valve implantation. Clinical and echocardiographic follow up was
obtained at 30 days. Outcomes were reported according to the Valve Academic Research
Consortium guidelines.
Results: All 15 device implants were successful. Aortic valve area increased from 0.7
0.2 cm2 to 1.5 0.2 cm2 (p 0.001) and mean trans-aortic gradient decreased from
42.2  10.3 mmHg to 11.9  5.3 mmHg (p  0.001). No patient had more than mild
paravalvular regurgitation. Hospital discharge occurred at 3 (2, 12) hospital days. At
30 days one patient had required a new pacemaker. There were no strokes, vascular
complications, transfusions, or deaths. All patients were in NYHA functional class I
or II at 30-day follow-up.
Conclusions: The ultra-low SAPIEN 3 transcatheter valve and delivery system may
facilitate fully percutaneous implantation in a broader range of patients with the potential
for more accurate positioning and less paravalvular regurgitation.
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Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe
aortic stenosis (AS). Restenosis after BAV can be resolved with another BAV or with
TAVI. We presented our experience with BAV and the results of RADAR-SLO study
where we evaluated the external beam radiation (EBRT) for prevention of restenosis.
Methods: Inclusion criteria for BAV were severe AS, increased operative risk, bridge to
surgical AVR/TAVI, urgent non-cardiac surgery. The severity of AS and LV function was
assessed with invasive and echocardiographic evaluation. In RADAR-SLO study we
randomized patients 2:1, the first group was treated with EBRT (total dose16Gy).
Results: 168 patients (age82.6y, LogEurosc22.1%) underwent BAV. After BAV we
observed an increase in AVA (0.59 to 0.70cm2, p0.05), a decrease in mean transval-
vular gradient (47.8 to 38mmHg, p0.05), without change of LV function (EF 53.3 to
54.9%, p0.75). The most common complications involved peripheral arterial accesses
(4.8%). BAV was performed in patients with CAD (N17) concomitant with PCI and in
patients with carcinoma (N7) that underwent major non-cardiac surgery. During 6
months follow up a restenosis of dilated valve occurred (restenosis rate 59%). Recurrence
of symptoms was resolved with another BAV (2 BAV N22, 3 BAV N3) or TAVI
(N22). During the follow up a trend towards better outcome was noted in the TAVI
patients. There was no impact of EBRT on restenosis and on survival rate (Fig.1).
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